Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mika Kamata-Sakurai

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Cancer Science|November 21, 2008
Differential effector mechanisms induced by vaccination with MUC1 DNA in the rejection of colon carcinoma growth at orthotopic sites and metastasesDaisuke Sugiura, Satoshi Aida, Kaori Denda-Nagai, et al.
Glycobiology|May 22, 2012
Mucin 21 in esophageal squamous epithelia and carcinomas: analysis with glycoform-specific monoclonal antibodiesYuan Tian, Kaori Denda-Nagai, Mika Kamata-Sakurai, et al.
The Journal of Biological Chemistry|April 15, 2010
Mucin 21/epiglycanin modulates cell adhesionYuri Yi, Mika Kamata-Sakurai, Kaori Denda-Nagai, et al.
Scientific Reports|March 23, 2022
In vivo imaging with two-photon microscopy to assess the tumor-selective binding of an anti-CD137 switch antibodyChisato Kaneko, Haruka Tsutsui, Kazuhisa Ozeki, et al.
Translational Oncology|July 12, 2022
In vivo validation of the switch antibody concept: SPECT/CT imaging of the anti-CD137 switch antibody Sta-MB shows high uptake in tumors but low uptake in normal organs in human CD137 knock-in miceAya Sugyo, Atsushi B Tsuji, Hitomi Sudo, et al.
Glycobiology|November 6, 2007
Identification and expression of human epiglycanin/MUC21: a novel transmembrane mucinYuichi Itoh, Mika Kamata-Sakurai, Kaori Denda-Nagai, et al.
Methods (San Diego, Calif.)|October 17, 2018
Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974Hirotake Shiraiwa, Atsushi Narita, Mika Kamata-Sakurai, et al.
Journal for Immunotherapy of Cancer|October 14, 2024
SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137Takayuki Kamikawa, Naoki Kimura, Shinya Ishii, et al.
Nature Medicine|October 2, 2012
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A modelTakehisa Kitazawa, Tomoyuki Igawa, Zenjiro Sampei, et al.
Cancer Immunology Research|April 1, 2024
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung CancerHirofumi Mikami, Shu Feng, Yutaka Matsuda, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Cancer Science|November 21, 2008
Differential effector mechanisms induced by vaccination with MUC1 DNA in the rejection of colon carcinoma growth at orthotopic sites and metastasesDaisuke Sugiura, Satoshi Aida, Kaori Denda-Nagai, et al.
Glycobiology|May 22, 2012
Mucin 21 in esophageal squamous epithelia and carcinomas: analysis with glycoform-specific monoclonal antibodiesYuan Tian, Kaori Denda-Nagai, Mika Kamata-Sakurai, et al.
The Journal of Biological Chemistry|April 15, 2010
Mucin 21/epiglycanin modulates cell adhesionYuri Yi, Mika Kamata-Sakurai, Kaori Denda-Nagai, et al.
Scientific Reports|March 23, 2022
In vivo imaging with two-photon microscopy to assess the tumor-selective binding of an anti-CD137 switch antibodyChisato Kaneko, Haruka Tsutsui, Kazuhisa Ozeki, et al.
Translational Oncology|July 12, 2022
In vivo validation of the switch antibody concept: SPECT/CT imaging of the anti-CD137 switch antibody Sta-MB shows high uptake in tumors but low uptake in normal organs in human CD137 knock-in miceAya Sugyo, Atsushi B Tsuji, Hitomi Sudo, et al.
Glycobiology|November 6, 2007
Identification and expression of human epiglycanin/MUC21: a novel transmembrane mucinYuichi Itoh, Mika Kamata-Sakurai, Kaori Denda-Nagai, et al.
Methods (San Diego, Calif.)|October 17, 2018
Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974Hirotake Shiraiwa, Atsushi Narita, Mika Kamata-Sakurai, et al.
Journal for Immunotherapy of Cancer|October 14, 2024
SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137Takayuki Kamikawa, Naoki Kimura, Shinya Ishii, et al.
Nature Medicine|October 2, 2012
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A modelTakehisa Kitazawa, Tomoyuki Igawa, Zenjiro Sampei, et al.
Cancer Immunology Research|April 1, 2024
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung CancerHirofumi Mikami, Shu Feng, Yutaka Matsuda, et al.
Pageof 2